View details of this raise on Seedstage

Fremonth, NH

Developing non-surgical technology for rapid, precise cancer tumor treatment.

• Mission: Developing a non-invasive, 10-minute cancer treatment that offers a safer, less invasive alternative to traditional therapies, aiming to revolutionize oncology care.  
• Innovation: Utilizing nanoparticle-based technology to precisely target tumors and eliminate cancer cells without damaging surrounding healthy tissue.  
• Market Opportunity: SynergyMed plans to enter the veterinary market by late 2024, with future plans to pursue FDA approval for human applications by 2026.  
• Clinical Validation: Preclinical trials on mice and dogs have shown rapid tumor reduction, validating the effectiveness of this innovative treatment approach.  
• Strategic Partnerships: Collaborating with prestigious institutions like Tufts and Harvard, with support for insurance reimbursement through CPT codes.  
• Impact: Positioned to provide a groundbreaking, minimally invasive solution for cancer patients, improving both outcomes and quality of life.

SynergyMed is pioneering a non-surgical, 10-minute cancer treatment technology that targets tumors with precision, leaving surrounding tissue unaffected. Successful preclinical trials on mice and dogs have demonstrated rapid tumor reduction, with plans to enter the veterinary market by late 2024 and pursue FDA approval for human applications by 2026. This patent-pending technology leverages nanoparticle-based methods to deliver an innovative, minimally invasive solution for oncology, aiming to provide patients with a safer and less invasive alternative to traditional cancer treatments.

The funds raised in this offering will accelerate SynergyMed’s path to commercialization by supporting further product development, certification, and collaborative research with leading U.S. institutions, including Tufts and Harvard. With CPT codes available for potential insurance reimbursement, SynergyMed is well-positioned to disrupt cancer treatment with a groundbreaking solution designed to improve patient outcomes and quality of life.

Company Info

SynergyMed develops non-invasive technology for rapid tumor elimination, targeting both veterinary and human oncology markets.

SynergyMed is a Boston-based medical technology company developing a non-invasive cancer treatment aimed at effectively eliminating tumors without the need for surgery. Using a patent-pending technology, SynergyMed has shown success in preclinical studies on mice and dogs, demonstrating the rapid disappearance of cancerous tumors without damaging surrounding tissue. This novel treatment, which involves targeted nanoparticles, has the potential to minimize the physical and emotional strain often associated with traditional cancer therapies.

SynergyMed is actively pursuing entry into the veterinary oncology market by late 2024, with an aim to secure FDA approval for human applications by 2026. The company has established collaborations with leading institutions, including Tufts and Harvard, and has received recognition from several startup competitions for its innovation in oncology. With reimbursement possibilities from Medicare and commercial insurance, SynergyMed is positioned to introduce a groundbreaking option in cancer treatment, offering hope to patients and paving the way for less invasive solutions in oncology.